FDA Clears Updated AI Software for MRI Neuroimaging
Offering enhanced deep learning technology, the updated NeuroQuant 5.0 software reportedly bolsters segmentation capabilities for amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated NeuroQuant® 5.0 software, which offers enhanced magnetic resonance imaging (MRI)-based artificial intelligence (AI) capabilities for assessing patients being treated for Alzheimer’s disease and other neurological conditions.
NeuroQuant 5.0 features advanced segmentation and quantification for amyloid-related imaging abnormalities (ARIA) detected on brain MRI scans of patients being treated with anti-amyloid therapies for Alzheimer’s disease, according to Cortechs.ai, the manufacturer of the software.
The newly FDA-cleared NeuroQuant 5.0 software reportedly features advanced segmentation and quantification for amyloid-related imaging abnormalities (ARIA) for patients with Alzheimer’s disease as well as integration of of susceptibility-sensitive MRI sequences that enhance detection of smaller brain lesions, according to Cortechs.ai, the manufacturer of the software. (Image courtesy of Cortechs.ai.)
The company adds that the deep learning capabilities within NeuroQuant 5.0 facilitate improved visualization of lesions associated with traumatic brain injury (TBI), ARIA-E, ARIA-H and cerebral amyloid angiopathy. Another benefit of the NeuroQuant 5.0 software involves the integration of susceptibility-sensitive MRI sequences that enhance detection of smaller brain lesions, according to Cortechs.ai.
"With this release, we are transforming the way radiologists and neurologists approach neurological evaluations, helping to ensure more accurate and timely diagnoses for patients,” noted Kyle Frye, the chief executive officer at Cortechs.ai.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
